ID: ALA1672081

Max Phase: Preclinical

Molecular Formula: C21H9BrN2OS

Molecular Weight: 417.29

Molecule Type: Small molecule

Representations

Canonical SMILES:  N#CC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(Br)cc4)ccc2c13

Standard InChI:  InChI=1S/C21H9BrN2OS/c22-11-4-6-12(7-5-11)26-17-9-8-14-18-13(17)2-1-3-15(18)20-19(14)16(10-23)21(25)24-20/h1-9H

Standard InChI Key:  CUHJCLMNTIZWTC-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 417.29

Molecular Weight (Monoisotopic): 415.9619

AlogP: 5.37

#Rotatable Bonds: 2

Polar Surface Area: 53.22

Molecular Species: NEUTRAL

HBA: 3

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 3

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa:

CX LogP: 4.94

CX LogD: 4.94

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.56

Np Likeness Score: -0.90

References

1. Zhang Z, Wu G, Xie F, Song T, Chang X..  (2011)  3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure-activity relationship studies.,  54  (4): [PMID:21235240] [10.1021/jm101181u]

Source

Source(1):

• Scientific Literature